Advaxis Chairman/CEO Thomas A. Moore Outlined Strategic Plan at the 2010 Rodman & Renshaw Global Healthcare Conference

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Yesterday, at the 2010 Rodman & Renshaw Global Healthcare Conference at the NY Palace Hotel in New York City, Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, outlined the company’s corporate strategy in a new company presentation.

“Management believes the quality of news stemming from the anticipated scientific milestones to be achieved in the next few quarters, coupled with the recently disclosed clinical trial survival reporting schedule, starting in the second quarter of 2011 will define the great promise of our Listeria platform technology.”

Some of the salient points of the corporate strategy discussed at the presentation included the following:

Continue to create proprietary and patented live bacterial immunotherapeutics to combat cancer
Use commercial partnerships to build value through licensing
Increase awareness of Listeria immunotherapies through research collaborations
Aggressively expand and defend current intellectual property
Expand platform technology to include other cancer and infectious disease indications

For more information on Advaxis’ corporate strategy, please visit the company’s website at www.advaxis.com. This new presentation was filed with the US Security and Exchange Commission on Tuesday, September 14, 2010.

“We are thankful to the Rodman healthcare banking team for having given us the opportunity to present our story to the healthcare value investors and institutions in attendance on the eve of one of the most important forward-looking twelve months in Advaxis history,” commented Advaxis Chairman/CEO Thomas A. Moore. “Management believes the quality of news stemming from the anticipated scientific milestones to be achieved in the next few quarters, coupled with the recently disclosed clinical trial survival reporting schedule, starting in the second quarter of 2011 will define the great promise of our Listeria platform technology.”

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.